AI
Friday, January 16, 2026 8:07:52 PM
Gro,
Thanks for sharing your free expertise on clinical trials again, but we’ll leave the analyses & conclusions to the independent peer reviewers, the
FDA, & the respected physicians who led the trial.
Dr. Ashkan
Dr. Liau
To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.
☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.
☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.
☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the primary endpoint.
Thanks for sharing your free expertise on clinical trials again, but we’ll leave the analyses & conclusions to the independent peer reviewers, the
FDA, & the respected physicians who led the trial.
Dr. Ashkan
Dr. Liau
To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.
☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.
☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.
☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the primary endpoint.
Bullish
I am a long NWBO shareholder. Views expressed are my own, and I have no affiliation with the company.
